Patent waiver in WTO to enable timely availability of Covid vaccines: Govt

India said temporary waiver of certain provisions of intellectual property rights under a WTO agreement would be an important step to enable scaling up of Covid-19 vaccines manufacturing

Topics

WTO India | World Trade organisation | Coronavirus Vaccine

India on Thursday said temporary waiver of certain provisions of intellectual property rights under a WTO agreement would be an important step to enable scaling up of manufacturing and timely availability of affordable COVID-19 vaccines and essential medical products.

In view of the COVID-19 crisis, India and South Africa had on October 2 last year proposed in WTO a relaxation in norms of the TRIPS agreement to ensure quick and affordable access to vaccines and medicines for developing countries.

India welcomed the US government’s support for this initiative.

“We are hopeful that with a consensus based approach, the waiver can be approved quickly at the WTO. The waiver is an important step for enabling rapid scaling up of manufacture and timely availability of affordable Covid-19 vaccines and essential medical products,” the commerce and industry ministry said in a statement.

The proposal has received support of more than 120 countries.

“We welcome the US government supporting this initiative and joining 120 other countries working towards affordable COVID-19 vaccines,” Commerce and Industry Minister Piyush Goyal tweeted.

The statement also said during his phone call with US President Joe Biden on April 26, Prime Minister Narendra Modi informed him about India’s initiative at the WTO which was aimed at the benefit of humanity.

The Biden administration has backed the initiative by India and South Africa at the WTO to temporarily waive patent rules on COVID-19 vaccines, seen as a breakthrough in the global fight against the deadly pandemic by potentially expanding the supply of the vaccines and more affordable doses for less wealthy nations.

Announcing the major policy decision after intense internal debate and strong pushback from American drugmakers, US Trade Representative Katherine Tai on Wednesday said that this is a global health crisis and the extraordinary circumstances of the pandemic call for extraordinary measures.

In October 2020, India and South Africa submitted a proposal suggesting a waiver for all WTO (World Trade Organization) members on the implementation, application and enforcement of certain provisions of the TRIPS Agreement in relation to the prevention, containment or treatment of COVID-19.

The agreement on Trade-Related Aspects of Intellectual Property Rights or TRIPS came into effect in January 1995.

It is a multilateral agreement on intellectual property (IP) rights such as copyright, industrial designs, patents and protection of undisclosed information or trade secrets.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor